Faculty Profile

Steven E. Canfield M.D.

Assistant Professor
Division of Urology
Department of Surgery

Chief of Urology
Lyndon B. Johnson General Hospital

Steven E. Canfield M.D. is an Assistant Professor of Surgery in the Division of Urology. Dr. Canfield is board certified in Urology and fellowship trained in Urologic Oncology by MD Anderson Cancer Center. His specialties include prostate cancer and robotic surgery, bladder cancer and kidney cancer.

Undergraduate Education

1992 B.S. - Haverford College Major: Biology (Honors)
1996 M.D. - Jefferson Medical College

Graduate Education

1996 M.D. - Jefferson Medical College

POSTGRADUATE TRAINING

1996-1998 Intern & Junior Resident, Dept. of Surgery,
Mt. Sinai School of Medicine, New York, NY
1998-2002 Resident & Chief Resident, Dept. of Urology,
Mt. Sinai School of Medicine, New York, NY
2002-2005 Fellow, Urologic Oncology
MD Anderson Cancer Center, Houston, TX

ACADEMIC APPOINTMENTS

Assistant Professor
Division of Urology, Department of Surgery
The University of Texas Medical School at Houston, Houston TX
August 2005 to present

Chief of Urology
Lyndon B. Johnson General Hospital
Harris County Health District
Houston TX
August 2006 to present

Adjunct Assistant Professor
Department of Urology
The University of Texas MD Anderson Cancer Center
Houston TX
August 2005 to November 2007

Assistant Professor
Department of Urology
The University of Texas MD Anderson Cancer Center
Houston TX
December 2007 to present

HOSPITAL APPOINTMENTS

8/2005-present Hermann Memorial Hospital
Lyndon B. Johnson General Hospital
MD Anderson Cancer Center

LICENSURE

New York State Medical License: #210496 - inactive
Texas State Medical License: # L9123
Pennsylvania State Medical License: #MD428546 -inactive
Florida State Medical License: #ME99268

CERTIFICATIONS

Diplomate, American Board of Urology
Certification Exam, Part II
February 2007

American Board of Urology
Certification Exam, Part I
June 2002

Diplomate, National Board of Medical Examiners
July 1997

PROFESSIONAL ORGANIZATIONS

American Urology Association, 1998
South Central Section of the AUA, 2005
Society of Urologic Oncology, 2005
Southwest Oncology Group, 2006

HONORS AND AWARDS

1991: Merck Summer Science Research Fellow

1996: The Paul D. Zimskind Memorial Prize in Urology, Dept. of Urology, Jefferson Medical College

2000: The Ferdinand C. Valentine Essay Contest - Third Prize - Basic Science

2001: The Ferdinand C. Valentine Essay Contest - Second Prize - Basic Science

2002: The Praecis Scholar Award

2004: The AACR Scholar-in-Training Award

2006: The LBJ General Hospital Outpatient Clinic - “Best patient satisfaction” Award

EDITORIAL POSITIONS:

2005:   Urologic Oncology - reviewer
2006:   Urology - reviewer
2007:   Surgical Oncology - reviewer
2008:   Journal of Urology - reviewer
2008:   Medscape Journal of Urology – reviewer
2008:   AUA Office of Education – content reviewer

CURRENT TEACHING RESPONSIBILITIES

Faculty, Division of Urology, Department of Surgery, University of Texas Health Science Center at Houston, Medical School
August 2005 - present

Course Director, Monthly Resident Research Conference
Division of Urology, Department of Surgery, University of Texas Health Science Center at Houston, Medical School
August 2005 – June 2007

Trainee, Teaching and Leading EBM: A Workshop for Teachers and Champions of Evidence-Based Medicine
DUKE Program on Teaching EBM
DUKE University Medical Center
April 22-25, 2008

Facilitator, EBM Workshop for Chief Residents
University of Texas Health Science Center at Houston, Medical School
May 22-23, 2008

Course Director, Urology Residency Evidence-Based Medicine Curriculum
Division of Urology, Department of Surgery, University of Texas Health Science Center at Houston, Medical School
August 2008 - present

Facilitator, Literature Appraisal Course
Clinical Research Curriculum, University of Texas Health Science Center at Houston, Medical School
December, 2008 – February, 2009

Facilitator, MD Anderson/UT Houston EBM Workshop
MD Anderson Cancer Center and University of Texas Health Science Center at Houston, Medical School
February 27 – March 1, 2009

Co-Faculty, Evidence Based Decision-Making in Urology: How to Find and Apply the Best Evidence in Caring for Your Patients
AUA Annual Meeting, Chicago, Illinois
April 26, 2009

Tutor – Trainee,
Evidence-Based Medicine: A Workshop for Urologists
AUA Headquarters, Linthicum, Maryland
August 28-29, 2009

GRANT SUPPORT:

Role: Co-Investigator
Title: Clinical Study to Evaluate the Ability of Muse to Decrease Erectile Function Recovery Time in Post-Radical Prostatectomy Patients
Primary Investigator: Run Wang, MD, FACS
Funding Agency: VIVUS, Inc.
Award Period: 3/10/06 – present
Amount: $117,655.89

Role: Site Primary Investigator Title: Prostate Serum/Tissue Bank in Underserved Minority Populations
Primary Investigator: Curtis Pettaway, MD
Funding Agency: CDC
Award Period: 9/30/06 – 9/29/08
Amount: $71,201.00

Role: Co-Investigator
Title: HSC-MS-07-0059 - LBJ Patient History Database - Serum/DNA Bank
Primary Investigator: Karin Hahn, MD
Funding Agency:
Award Period: 2/07/08 – present
Amount: TBD

Role: Co-Investigator
Title: Premature ejaculation study
Primary Investigator: Run Wang, MD
Funding Agency:
Award Period: January 2008 - present
Amount: TBD

Role: Primary Investigator
Title: LBJ Clinical Research Outreach Program in Urologic Oncology
Funding Agency: University Cancer Fund, MDACC
Award Period: September 2008 – August 2009
Amount: $82,000

Service on Committees:

UT-HMS AFFILIATED HOSPITALS

Harris County Cancer Committee, 2006-present
Memorial Hermann Hospital Cancer Committee, 2006-07
LBJGH Executive Committee 2007-present
LBJGH Chief’s Committee 2007-present
LBJGH OR Committee 2007-present
LBJGH Oncology Steering Committee 2008-present
Harris County Executive Medical Board 2008-present

INVITED PRESENTATIONS:

Clinical Surveillance After Radical Nephrectomy. Presented at the Kidney Cancer Association Survivor and Patient Conference, Houston, TX, September 10, 2005.

Current Topics in Testicular Cancer. Presented at the Current Advances in Urology – A Symposium for Chinese University Urologist Training College, Houston, TX, May 16, 2006.

The Role of Metastasectomy for Renal Cell Carcinoma. Presented at the Kidney Cancer Association Survivor and Patient Conference, Houston, TX, January 9, 2007.

Prostate Cancer Treatment 2007 – State of the Art: Proton Radiation and Robotic Surgery. Presented at the MD Anderson Pelvic Health Seminar, Houston, TX, September 20, 2007

Urology: A Comprehensive Overview. Presented at the Surgical Student Lecture Series UT Medical School, Houston, TX, October 11, 2007.

Hematuria: An Evidence Based Approach to the Urologic Work-up. Presented at the Internal Medicine Grand Rounds, UT Medical School, Houston, TX, October 25, 2007.

Clinical Research in Genitourinary Oncology at LBJ General Hospital: Challenges and Opportunities. Presented at the Genitourinary Cancer Conference, MD Anderson Cancer Center, Houston, TX, May 2008.

The Evidence for Localized Prostate Cancer. Presented at Family and Community Medicine Grand Rounds, UT Medical School, Houston, TX, June 4, 2008.

Prediction and Treatment of Localized Prostate Cancer Using Evidence Base Medicine. Presented at the Division of Urology Grand Rounds, UT Medical School at Houston, TX, July 10, 2008.

Minimally Invasive New Technology in Oncologic Surgery: Urology Report. Presented at the MINTOS Conference, MD Anderson Cancer Center, Houston, TX, July, 2008.

Localized Prostate Cancer: A Perspective on Evidence Based Clinical Practice. Presented at General Surgery Grand Rounds, UT Medical School, Houston, TX, July 31, 2008.

Can Prostate Cancer Be Prevented? Presented at the Prostate Cancer Awareness Conference, MD Anderson Cancer Center, Houston, TX, September 11, 2008.

Role of Lymph Node Dissection in the Surgical Management of Renal Cell Carcinoma. Presented at the Urologic Oncology: Advances in Clinical Practice seminar, MD Anderson Cancer Center, Houston, TX, October 25-26.

PUBLICATIONS:

Abstracts:

1. Santer UV, Tate D, Canfield S, Kansil S, and Santer M: Base Changes at Position
529, but not 527 or 528, in 16S RNA are Highly Deleterious for Growth and
Protein Synthesis. FASEB Journal, Abstracts, 7.7: 1093, 1993.

2. Canfield SE, Hassen W, Atkinson G, and Hall SJ: Tumor Cell Expression of Fas
as a Target for Prostate Cancer Gene Therapy. Journal of Urology, 163 (4) Supp.:
37-38, 2000.
Presented at the 2000 annual meeting of the American Urological Association,
April 29 - May 4.

3. Hall SJ, Yan Y, Canfield SE, and Chen S-H: A Role for Fas/FasL Interactions in a
Bystander Effect Following the Combination of Ad.HSV-tk + GCV and Ad.IL-12.
Molecular Therapy, 1 (5) : S128, 2000.

4. Canfield SE, Hassen W, Yan Y and Hall SJ: HSV-TK and IL-12 Gene Therapy
Orchestrate a Bystander Effect Through Fas and FasL Interactions in
Experimental Prostate Cancer. Journal of Urology 165 (5) Supp.: 142, 2001.
Presented at the 2001 annual meeting of the American Urologic Association,
June 2-7.

5. Cohen DD, Canfield SE, Sanchez-Ortiz RF, Madsen LT, Swanson DA and Wood CG: Aggressive Resection for Locally Advanced Renal Cell Carcinoma. Journal of Urology, 169(4) Supp.: 175, 2003.

6. Canfield SE, Williams SA, McConkey DJ: Bortezomib Combined with Docetaxel: Inhibition of Efficacy Via Cell Cycle Arrest in Experimental Prostate Cancer. Minisymposium presentation at the 2004 annual meeting of the American Association for Cancer Research.

7. Canfield SE, Kamat AM, Sanchez-Ortiz RF, Swanson DA and Wood CG: Renal Cell Carcinoma with Nodal Metastases in the Absence of Distant Metastatic Disease (Clinical Stage TXN1-2M0): Predictive Factors for Survival. Journal of Urology 171(4) Supp.: 472, 2004. Presented at the 2004 annual meeting of the American Urologic Association.

8. Kent D, Canfield SE, Troncoso P and Babaian RJ: Comparative Analysis of the Pathologic Features of Biopsy Proven Gleason 8 or Greater Prostate Cancer Between 1991 – 2004. Presented at the 2005 annual meeting of the South Central Section of the American Urologic Association.

9. Kasraeian A, Pendleton J, Wludyka P, Anai S, Nakamura K, Canfield SE, Rosser CJ: Knowledge and Attitudes of Primary Care Physicians Regarding Prostate Cancer Screening. Presented at the 2006 annual meeting of the South Eastern Section of the American Urologic Association.

Book Chapters & Reviews:

1. Canfield SE (Ed.): Commonly Used Medications, In Gomella LG, and Lefor AT
(Ed.) Surgery On Call, second edition, Appleton and Lange, Stamford, CT, 1996.

2. Droller MJ and Canfield SE: Where We Stand with Tumor Markers for Urothelial
Malignancy. Contemporary Urology, 14 (4): 63 - 82, 2002.

3. Canfield SE, Dinney CPN and Droller MJ: Surveillance and Management of Recurrence for Upper Tract Transitional Cell Carcinoma. Urologic Clinics of North America, 30(4): 791-802, 2003.

4. Canfield SE and Matin SF: Urologic Cancers: When is Laparoscopic Treatment the Standard of Care? (Cover Story) Contemporary Urology, 17(3): 38-57, 2005.

Peer Reviewed Articles:

1. Das A, Strup S, Canfield S, Mulholland SG, and Gomella LG: Utilization of Autologous Blood Donation During Radical Retropubic Prostatectomy.
Techniques in Urology, 4(3): 131-135, 1998.

2. Sanford MA, Yan Y, Canfield SE, Hassen W, Selleck WA, Atkinson G, Chen SH,
and Hall SJ: Independent Contributions of Gr-1+ Leukocytes and Fas/FasL
Interactions to Induce Apoptosis Following Interleukin-12 Gene Therapy in a
Metastatic Model of Prostate Cancer. Human Gene Therapy, 12(12): 1485 -1498, 2001.

3. Canfield SE, Gans WH, Unger P, and Hall SJ: Postradiation Prostatic Sarcoma:
De Novo Carcinogenesis or Dedifferentiation of Prostatic Adenocarcinoma?
Techniques in Urology, 7(4): 294 - 295, 2001.

4. Hall SJ, Canfield SE, Yan Y, Hassen W, Selleck WA and Chen S-H: A Novel
Bystander Effect Involving Tumor-Cell Derived Fas and FasL Interactions
Following Ad.HSV-tk and Ad.IL-12 Gene Therapies in Experimental Prostate
Cancer. Gene Therapy, 9(8): 511- 517, 2002.

5. Selleck WA, Canfield SE, Hassen WA, Meseck M, Kuzmin AI, Eisensmith RC,
Chen SH, Hall SJ: IFN-gamma Sensitization of Prostate Cancer Cells to Fas
Mediated Death: A Gene Therapy Approach. Molecular Therapy, 7(2): 185-92, 2003.

6. Sanchez-Ortiz R, Madsen LT, Swanson DA, Canfield SE and Wood CG: Closed
Suction or Penrose Drainage after Partial Nephrectomy: Does it Matter? Journal
of Urology, 171(1): 244-246, 2003
7. Canfield SE, Kamat AM, Sánchez-Ortiz RF, Detry M, Swanson DA and Wood CG: Renal Cell Carcinoma With Nodal Metastases in the Absence of Distant Metastatic Disease (Clinical Stage TxN1-2M0): The Impact of Aggressive Surgical Resection on Patient Outcome. Journal of Urology, 175 (3): 864-869, 2006.
8. Canfield SE, Zhu K, Williams SA and McConkey DJ: Bortezomib Inhibits Docetaxel-Induced Apoptosis Via a p21-Dependent Mechanism in Human Prostate Cancer Cells. Molecular Cancer Therapeutics, 5(8): 2043-2050, 2006.

9. Taylor LG, Canfield SE, Du, XL: Review of Major Adverse Effects of Androgen Deprivation Therapy in Men with Prostate Cancer. Submitted for publication.

10. Hinh, P, DeSouza, R, Canfield SE: Squamous Cell Carcinoma of the Renal Pelvis in the setting of Xanthogranulomatous Pyelonephritis. Submitted for publication.